ReviewExpert opinion on therapeutic targets2010
The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.
Review in Expert opinion on therapeutic targets, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 206 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
206 citing papers in PubMed.
- Circular RNA Circ_0020236 Inhibits Hepatocellular Carcinoma Cell Proliferation and Migration Through Modulating the MiR-1825/IKBKB Axis.Biochemical genetics · 2026Article
- Article
- NF-κB activation and cytokine dysregulation: a pathogenic loop in breast cancer inflammation - a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Differential Protumoral Mechanisms Induced by CAFs in Cervical Cancer Cells Occur Independently of 17β-Estradiol Stimulation.Cancers · 2026Article
- Review
- Integrative Computational and Transcriptional Analysis of NF-κB and HIF-1α Modulation Following Doxorubicin Treatment in Triple-Negative Breast Cancer Cells.Journal of experimental pharmacology · 2026Article
- From granulomas to tumors: post-tuberculosis immune and structural lung remodeling as a driver of carcinogenesis.Frontiers in immunology · 2026Review
- Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Tumor Necrosis Factor-Alpha's Role in the Pathophysiology of Colon Cancer.Diseases (Basel, Switzerland) · 2025Review
- Cysteine Alkylation in Enzymes and Transcription Factors: A Therapeutic Strategy for Cancer.Cancers · 2025Review
- Phytochemicals Targeting Inflammatory Pathways in Alcohol-Induced Liver Disease: A Mechanistic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Investigating Natural Product Inhibitors of IKKα: Insights from Integrative In Silico and Experimental Validation.Molecules (Basel, Switzerland) · 2025Article
- Bioactive Potential of Sweet Cherry (Foods (Basel, Switzerland) · 2025Article
- SAA1 Protein: A Potential Biomarker for Acute Myeloid Leukemia.Biomedicines · 2025Article
- Targeting the ERK1/2 and p38 MAPK pathways attenuates Golgi tethering factor golgin-97 depletion-induced cancer progression in breast cancer.Cell communication and signaling : CCS · 2025Article
- Post-translational governance of NF-κB in cancer immunity: mechanisms and therapeutic horizons.Frontiers in immunology · 2025Review
- Baicalein Inhibits Proliferation, Migration, and Invasion of Mesothelioma Cells Through the p53-FOXM1 Signaling Axis.Cancer management and research · 2025Article
- The Effects of Probiotic-Prebiotic Use on Acute Inflammatory Parameters in Patients Receiving Pelvic Radiotherapy: A Prospective Multicenter Study.Mediators of inflammation · 2025Article
- Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Brewers' Yeast (Aquaculture nutrition · 2025Article
146 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
importance of the fieldNuclear factor kappa B (NF-kappaB) is activated by a variety of cancer-promoting agents. The reciprocal activation between NF-kappaB and inflammatory cytokines makes NF-kappaB important for inflammation-associated cancer development. Both the constitutive and anticancer therapeutic-induced NF-kappaB activation blunts the anticancer activities of the therapy. Elucidating the roles of NF-kappaB in cancer facilitates developing approaches for cancer prevention and therapy. AREAS COVERED IN THIS REVIEW: By searching PubMed, we summarize the progress of studies on NF-kappaB in carcinogenesis and cancer cells' drug resistance in recent 10 years. WHAT THE READER WILL GAIN: The mechanisms by which NF-kappaB activation pathways are activated; the roles and mechanisms of NF-kappaB in cell survival and proliferation, and in carcinogenesis and cancer cells' response to therapy; recent development of NF-kappaB-modulating means and their application in cancer prevention and therapy. TAKE HOME MESSAGE: NF-kappaB is involved in cancer development, modulating NF-kappaB activation pathways has important implications in cancer prevention and therapy. Due to the complexity of NF-kappaB roles in different cancers, careful evaluation of NF-kappaB's in each cancer type is crucial in this regard. More cancer cell-specific NF-kappaB inhibiting means are desired for improving anticancer efficacy and reducing systemic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.